Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.

ABSTRACT:

Objectives

To evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III randomised study of Japanese patients with episodic migraine (EM) or chronic migraine (CM).

Design

Multicentre open-label study.

Setting

A total of 41 centres in Japan.

Participants

Patients completing the DBTP continued into the 28-week open-label treatment period (OLTP). 254 of 261 (97.3%) randomised patients continued into the OLTP; 244 (93.5%) completed treatment.

Interventions

Once-monthly subcutaneous erenumab 70 mg.

Main outcome measures

Changes from baseline in monthly migraine days (MMD) and monthly acute migraine-specific medication treatment days (MSMD) reported via patient eDiary;

SUBMITTER: Hirata K 

PROVIDER: S-EPMC10441051 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature